Back to top
more

Biocept, Inc. (BIOC)

(Delayed Data from NSDQ)

$0.91 USD

0.91
317,349

+0.01 (1.10%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Biocept, Inc. [BIOC]

Reports for Purchase

Showing records 41 - 60 ( 65 total )

Company: Biocept, Inc.

Industry: Medical Services

Record: 41

05/24/2016

Company Report

Pages: 6

New Test and New Pharma Agreement; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 42

05/24/2016

Company Report

Pages: 6

New Test and New Pharma Agreement; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 43

05/19/2016

Company Report

Pages: 6

1Q 2016 Financial Results; Reiterate Buy But Adjusting Price Target to $2.50

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 44

05/19/2016

Company Report

Pages: 6

1Q 2016 Financial Results; Reiterate Buy But Adjusting Price Target

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 45

05/13/2016

Company Report

Pages: 9

Q1 volumes inline, sales fell short, lower to BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 46

03/31/2016

Company Report

Pages: 5

Clinical Advisory Board of Expert Oncologists Formed; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 47

03/31/2016

Company Report

Pages: 5

Clinical Advisory Board of Expert Oncologists Formed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 48

03/23/2016

Company Report

Pages: 5

Biopharma Clinical Trial Collaboration; Israeli Distribution; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 49

03/23/2016

Company Report

Pages: 5

Biopharma Clinical Trial Collaboration; Israeli Distribution; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 50

03/10/2016

Company Report

Pages: 5

Solid Test Volume Growth in 2015; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 51

03/10/2016

Company Report

Pages: 8

Q3 results missed, but underlying metrics encouraging

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 52

01/08/2016

Company Report

Pages: 5

Prostate Cancer Test Launched; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 53

11/18/2015

Company Report

Pages: 5

New NSCLC Treatment Expands Market for Biocept; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 54

11/06/2015

Company Report

Pages: 8

Q3 results missed, but underlying metrics encouraging

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 55

09/15/2015

Company Report

Pages: 5

Additional Payer Agreements; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 56

08/19/2015

Company Report

Pages: 27

We are initiating coverage with a Buy rating and a 12-month price target of $4 per share

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 75.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 57

08/11/2015

Company Report

Pages: 8

Q2 results mixed, new metrics detailed, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 58

05/13/2015

Company Report

Pages: 8

Q1 results mixed, underlying trends positive, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 59

03/10/2015

Company Report

Pages: 8

Q4 commercial tests ahead of model, recent raise puts sufficient capital in place

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Biocept, Inc.

Industry: Medical Services

Record: 60

11/14/2014

Company Report

Pages: 8

Q3 results, lung cancer test launched, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party
// eof